Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients
Article Abstract:
The Retrospective chart review of experienced patients on didanosine (ddl) plus stavudine (d4T) was conducted at a single institution to record the development of adverse events as well as their severity and action taken, is presented. Multiexperienced patients treated with combinations, including ddl plus d4T frequently develop drug-related toxicity but these events are rarely severe and so the drugs could still be considered a valid option for salvage regimens.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Article Abstract:
A study was conducted to explore the antiretroviral activity and safety of MK-0518 versus placebo for 10 days as monotherapy in antiretroviral therapy-naive HIV-1-infected patients with plasma HIV-1 RNA levels of at least 5000 copies/mL and CD[4.sup.plus] T-cell counts of at least 100 cells/m[m.sup.3]. MK-0518 was found to reveal potent antiretroviral activity as short-term monotherapy and was generally well tolerated at all doses.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy
Article Abstract:
Taking didanosine once a day instead of twice a day may still be effective and will reduce the number of pills HIV patients must take. A lower dose per day will also reduce the number of side effects from the drug. The lower dose can be used because most HIV patients now take combination therapy.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
- Abstracts: Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells per cubic millimeter
- Abstracts: A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
- Abstracts: Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients
- Abstracts: Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy